This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

# **Revision of PRECAUTIONS**

# Telmisartan/amlodipine besilate/hydrochlorothiazide Telmisartan/hydrochlorothiazide

May 20, 2025

### Therapeutic category

Antihypertensives

#### Non-proprietary name

Telmisartan/amlodipine besilate/hydrochlorothiazide Telmisartan/hydrochlorothiazide

### Safety measure

PRECAUTIONS should be revised.

Current	Revision
8. IMPORTANT PRECAUTIONS	8. IMPORTANT PRECAUTIONS
(N/A)	Hydrochlorothiazide, which is an ingredient of this drug, may cause
	acute myopia, angle closure glaucoma, and/or choroidal effusion.
	Patients should be instructed to consult an ophthalmologist
	immediately if they experience abnormalities such as a rapid
	reduction in visual acuity and eye pain.
11. ADVERSE REACTIONS	11. ADVERSE REACTIONS
11.1 Clinically Significant Adverse Reactions	11.1 Clinically Significant Adverse Reactions
Acute myopia, angle closure glaucoma	Acute myopia, angle closure glaucoma, choroidal effusion
Acute myopia (including blurred vision and reduced visual acuity)	Acute myopia (including blurred vision and reduced visual acuity),
and/or angle closure glaucoma may occur. If abnormalities such as	angle closure glaucoma <u>, and/or choroidal effusion</u> may occur.
a rapid reduction in visual acuity and eye pain are observed,	
administration should be discontinued, and the patients should be	
instructed to consult an ophthalmologist promptly.	

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.